NAD+

NAD+ sits at the center of how cells convert food into usable energy. It acts as an electron acceptor in glycolysis, the TCA cycle, fatty acid oxidation, and oxidative phosphorylation — the core pathways that generate ATP, the cell's energy currency (5, 7). In its oxidized form (NAD+) it picks up electrons from metabolic intermediates and becomes NADH, which then delivers those electrons to the mitochondrial electron transport chain.

This redox role explains why NAD+ availability has such broad downstream effects. When NAD+ levels fall, the entire metabolic machinery slows: cells become less efficient at producing energy, the NAD+/NADH ratio shifts, and stress-response systems become impaired (10). Research has shown that disruptions in NAD+ homeostasis are associated with compromised adaptive stress responses, impaired neuronal plasticity, and reduced capacity for DNA repair (10).

Beyond its classic redox role, NAD+ is now understood to be a remarkably dynamic molecule — recent work suggests it has a half-life on the order of minutes in some tissues, indicating that cells are constantly synthesizing and consuming it (9). This rapid turnover may be why NAD+ status is so sensitive to nutritional, metabolic, and age-related changes.

The connection between NAD+ and aging is one of the most active areas in longevity research. NAD+ levels gradually decline with age in multiple tissues, and this decline has been linked causally to numerous age-associated diseases including cognitive decline, cancer, metabolic disease, sarcopenia, and frailty (6, 8). Importantly, many of these conditions can be slowed or even reversed by restoring NAD+ levels in preclinical models (6).

The mechanism appears to run through NAD+-consuming enzymes. Sirtuins — a family of proteins that regulate metabolism, stress resistance, and gene expression — depend on NAD+ to function, so when NAD+ falls, sirtuin activity falls with it (5, 6). PARPs, which use NAD+ to repair damaged DNA, become less effective. CD38, an NAD+-consuming enzyme that increases with age and inflammation, may itself be a major driver of the decline by accelerating NAD+ breakdown (5).

Restoring NAD+ levels has been shown to promote health and extend lifespan in laboratory studies, prompting researchers to describe NAD+ replenishment as a strategy for boosting general resilience rather than treating any single disease (8). Studies suggest the approach may improve cardiovascular health, support muscle function, and protect against neurodegeneration (1).

Because NAD+ itself is poorly absorbed when taken orally, much of the research has focused on precursors — molecules the body converts into NAD+. The most studied are nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN), both forms of vitamin B3 that feed into NAD+ biosynthesis pathways (1, 2). Direct intravenous NAD+ administration is also used in research and clinical settings to bypass the absorption problem.

Precursor supplementation has been shown to reliably elevate NAD+ levels in tissues, and in laboratory studies this elevation produces meaningful improvements in metabolic syndrome, cardiovascular function, neurodegeneration, and muscular strength (1). Clinical translation has been more measured — human trials confirm that precursors raise NAD+ levels effectively, but the magnitude of disease-modifying benefit seen in early-stage human studies has so far been smaller than what laboratory work suggested (1).

Researchers are actively investigating why this gap exists. One emerging factor is the gut microbiome, which appears to interact with orally administered NAD+ intermediates and may influence how much precursor actually reaches systemic circulation (1, 2). Another is the existence of multiple cellular compartments with distinct NAD+ pools — boosting whole-body NAD+ may not equally restore the specific subcellular pools where deficits matter most (2). Reduced-form precursors and alternative delivery strategies are being explored to address these challenges.

Beyond energy and aging, NAD+ plays critical roles in DNA repair and immune regulation. PARP enzymes use NAD+ to tag damaged DNA for repair, meaning NAD+ availability directly affects how well cells respond to genetic damage (5, 6). When DNA damage is heavy, PARP activity can drain cellular NAD+ pools, creating a feedback loop where damage accumulates faster.

In the immune system, CD38 — an NAD+-consuming enzyme expressed on immune cells — is heavily involved in immune responses and inflammation (5). Its activity rises with age and chronic inflammation, contributing to the gradual NAD+ decline observed in older tissues. This intersection of NAD+ metabolism and immune function may help explain why NAD+ depletion is implicated in such a wide range of conditions.

NAD+ has also been studied in the context of cancer metabolism, where the rate-limiting biosynthesis enzyme NAMPT is often elevated in tumors, and in inherited disorders of NAD+ biosynthesis, which can cause severe congenital problems (4, 5). The breadth of these connections reflects how deeply NAD+ is embedded in cellular function — virtually any process that depends on energy, repair, or signaling intersects with NAD+ at some level.

Reported side effects of NAD+ and its precursors in published research are generally mild — most clinical studies of NAD+ precursors have shown good tolerability, with occasional reports of flushing, nausea, or fatigue at higher doses. IV NAD+ administration can cause sensations of pressure or discomfort during infusion, which typically resolve when the infusion rate is slowed.

Long-term safety in humans hasn't been fully characterized, and researchers have noted that deeper understanding of how NAD+ is regulated across cellular compartments is still needed before broad recommendations can be made (2). There is also active discussion about whether sustained elevation of NAD+ might affect processes that depend on its turnover, such as inflammation and cellular senescence (9).

The body of NAD+ evidence comes from a mix of preclinical work, mechanistic studies, and a growing but still limited set of human clinical trials, with translation between the two not yet complete.